Quanterix announced “Simoa Accelerator” – a dedicated laboratory environment for clinical sample testing and development allowing broader access to an advanced diagnostic technology that has been fueling research in oncology, neurology, cardiology, infectious disease, etc.
Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the opening of The Simoa Accelerator, a dedicated laboratory environment for custom assay development and clinical sample testing. Designed to provide access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, this state-of-the-art facility allows users to experience the advantages of the technology firsthand.
With Simoa, life science researchers can explore biomarkers and pathways with greater sensitivity and precision, paving the way for the development of new diagnostic tests and improved treatment of diseases in oncology, neurology, cardiology and other fields of medicine. The Simoa Accelerator provides accessibility to this innovative technology, allowing customers to:
“The Simoa Accelerator provides immediate access to innovative, disruptive technology that is attracting a great amount of attention from academics, clinical researchers and scientists. During the initial pilot phase of this lab, Quanterix has already been able to undertake a significant number of projects with the majority of the leading global pharmaceutical companies and has achieved outstanding results. This unprecedented demand for Simoa is what led us to create and launch the Simoa Accelerator,” said Kevin Hrusovsky, Executive Chairman, Quanterix. “With new accessibility to the platform, we hope to accelerate the understanding and exposure of single molecule array technology so that end users can fully understand how Quanterix can help them to unlock a world of insight into disease detection, diagnosis and patient treatment.”
The Simoa Accelerator is now available at the Quanterix office in Lexington, Massachusetts. For more information, please visit: http://www.quanterix.com/literature/product-brochures/simoa-accelerator.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.